United Therapeutics Corporation ( NASDAQ: UTHR) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:10 PM EDT ...

By publishing complete response letters as soon as they are issued to drug sponsors, the FDA is expanding transparency in a ...

The U.S. Food and Drug Administration has declined to approve Scholar Rock's drug for a rare neuromuscular disease, citing ...

The U.S. Food and Drug Administration has declined to approve a higher-dose version of Biogen's drug for a rare genetic ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

The U.S. government has endorsed an obscure drug as a potential treatment for autism symptoms that medical researchers say ...

IRVINE, CA / ACCESS Newswire / September 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of deep venous ...

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout. The novel formulation of the stalwart ...

Ocugen (OCGN) is a clinical-stage biotech focused on modifier gene therapies for inherited retinal diseases, with key ...

MANILA: Women seeking to terminate unwanted pregnancies seem to have found solace in online selling platforms, where vendors ...

MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such ...